Compare Merck & Co., Inc. (MRK) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Williams Companies Inc — how do they compare? Merck & Co., Inc. trades at $146.19 (market cap $351.28B), while Williams Companies Inc trades at $72.85 (market cap $88.48B). The key difference: Merck & Co., Inc. is far larger — about 4× Williams Companies Inc's market cap, and Williams Companies Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Williams Companies Inc for 58 Days on average.
| MRK | WMB | |
|---|---|---|
Market Cap | $351.28B | $88.48B |
Volume | 7,969,665 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $156.43 | $79.40 |
52-Week Low | $82.49 | $56.51 |
Typical Hold Time | 98 Days | 58 Days |
Enterprise Value | $398.04B | $119.11B |
Dividend Yield | 2.39% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Williams Companies (WMB) trades at $72.67, up 1.69% today, with strong analyst support (79% buy ratings) and a consensus price target of $87.27. The stock shows bullish technical signals with support at $72 and resistance at $73. Fundamentally, WMB delivered $11.95B revenue in 2025 with 25.18% net income margin, though recent quarterly earnings were mixed with one beat and two misses. The company benefits from stable fee-based revenues in the midstream energy sector.
WMB presents a compelling opportunity with dividend growth potential and exposure to rising natural gas demand from data centers. However, investors face risks from energy market volatility and high debt levels. The stock trades at a premium valuation (P/E 28.82) but offers 3% dividend yield with consistent payout increases. Near-term catalysts include Q3 earnings and AI-driven power demand growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
